SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance. However, the contributions of histone methylatransferase SET and MYND domain containing 3 (SMYD3) to sorafenib resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shanshan, You, Xin, Liu, Xiaoshu, Fengwei Zhang, Zhou, Hongjuan, Shang, Xuechai, Cai, Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391607/
https://www.ncbi.nlm.nih.gov/pubmed/37534166
http://dx.doi.org/10.1016/j.isci.2023.106994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391607/
https://www.ncbi.nlm.nih.gov/pubmed/37534166
http://dx.doi.org/10.1016/j.isci.2023.106994

Ejemplares similares